Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,424.85 162.29 1.00%
S&P 500 1,862.31 19.33 1.05%
NASDAQ 4,086.22 52.06 1.29%
Ticker Volume Price Price Delta
STOXX 50 3,139.26 47.74 1.54%
FTSE 100 6,584.17 42.56 0.65%
DAX 9,317.82 144.11 1.57%
Ticker Volume Price Price Delta
NIKKEI 14,406.30 -11.38 -0.08%
TOPIX 1,167.92 1.37 0.12%
HANG SENG 22,749.87 53.86 0.24%

BioCryst to Present at Two Upcoming Investor Conferences



  BioCryst to Present at Two Upcoming Investor Conferences

Bank of America Merrill Lynch 2013 Healthcare Conference Jefferies Global
Healthcare Conference 2013

Business Wire

RESEARCH TRIANGLE PARK, N.C. -- May 09, 2013

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that executives
from BioCryst are scheduled to present and provide a corporate summary and
update regarding the Company’s clinical programs at the following investor
conferences:

  * Bank of America Merrill Lynch Healthcare Conference in Las Vegas on
    Thursday, May 16, 2013 at 9:20 a.m. Pacific Time
  * Jefferies Global Healthcare Conference in New York on Thursday, June 6,
    2013 at 10:30 a.m. Eastern Time

Links to a live audio webcast and replay of the presentation may be accessed
on the BioCryst website events page at
http://investor.shareholder.com/biocryst/events.cfm.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals designs, optimizes and develops novel small molecule
drugs that block key enzymes involved in infectious and inflammatory diseases,
with the goal of addressing unmet medical needs of patients and physicians.
BioCryst currently has two late-stage development programs: peramivir, a viral
neuraminidase inhibitor for the treatment of influenza, and ulodesine, a
purine nucleoside phosphorylase (PNP) inhibitor for the treatment of gout. In
addition, BioCryst has several early-stage programs: BCX4161 and a next
generation oral inhibitor of plasma kallikrein for hereditary angioedema and
BCX4430, a broad spectrum antiviral for hemorrhagic fevers. For more
information, please visit the Company's website at www.BioCryst.com.

This press release contains forward-looking statements, including statements
regarding future results and achievements. These statements involve known and
unknown risks, uncertainties and other factors which may cause our actual
results, performance or achievements to be materially different from any
future results, performances or achievements expressed or implied by the
forward-looking statements. Please refer to the documents BioCryst files
periodically with the SEC and located at
http://investor.shareholder.com/biocryst/sec.cfm.

BCRXW

Contact:

BioCryst Pharmaceuticals
Robert Bennett, +1-919-859-7910
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement